Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.63 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037636 | 0.88 | TGM2 (0.63) | TGM2 | |
| SCHEMBL6037629 | 0.80 | TGM2 (0.61) | TGM2 | |
| SCHEMBL6033954 | 0.79 | TGM2 (0.69) | TGM2 | |
| SCHEMBL6033956 | 0.78 | TGM2 (1.00) | TGM2 | |
| SCHEMBL6037618 | 0.77 | TGM2 (0.75) | TGM2 | |
| SCHEMBL6033953 | 0.72 | TGM2 (0.62) | TGM2 | |
| SCHEMBL6037624 | 0.72 | TGM2 (0.61) | TGM2 | |
| SCHEMBL6034920 | 0.71 | TGM2 (0.60) | TGM2 | |
| SCHEMBL6034313 | 0.70 | TGM2 (0.64) | TGM2 | |
| SCHEMBL6033371 | 0.68 | TGM2 (0.61) | TGM2MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | TGM2 1/4885MALT1 349/4885IDO1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.